Matches in SemOpenAlex for { <https://semopenalex.org/work/W3125304810> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W3125304810 abstract "Abstract Background Besides the clinical benefit of crizotinib in ALK-rearranged metastatic non-small cell lung cancer (NSCLC), concerns about its hepatotoxicity have arisen. It is not clear whether this is a drug class side effect or if the use of other selective ALKs inhibitors is safe after this serious adverse event. While evidence from clinical trials is scarce, reports of treatment after crizotinib-induces hepatitis may add to clinical decision. Case presentation Herein, we report a case of acute hepatitis induced by crizotinib in a 32-years-old female diagnosed with metastatic NSCLC, harboring the ALK-rearrangement. After 60 days of crizotinib therapy, the patient presented with acute hepatitis, diagnosed after investigation of non-specific symptoms, such as nausea and fatigue. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from baseline to 3010 IU/L and 9145 IU/L, respectively. Total bilirubin increased up to 7.91 mg/dL, but she did not develop liver failure. After crizotinib discontinuation, a gradual hepatic function recovery occurred. Unfortunately, during the period without specific oncology treatment, her disease showed an unequivocal progression. Therefore, she started on alectinib with great response, and no liver function alteration recurred. Conclusions This case suggests that alectinib, even belonging to the same drug class, could be used as an alternative agent when crizotinib is the etiology of liver damage, but more robust evidence has awaited." @default.
- W3125304810 created "2021-02-01" @default.
- W3125304810 creator A5030610788 @default.
- W3125304810 creator A5037608961 @default.
- W3125304810 creator A5040886031 @default.
- W3125304810 creator A5051401384 @default.
- W3125304810 creator A5083441342 @default.
- W3125304810 date "2021-01-28" @default.
- W3125304810 modified "2023-10-16" @default.
- W3125304810 title "Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report" @default.
- W3125304810 cites W1998048643 @default.
- W3125304810 cites W2050249255 @default.
- W3125304810 cites W2071385801 @default.
- W3125304810 cites W2074950286 @default.
- W3125304810 cites W2134787029 @default.
- W3125304810 cites W2150424194 @default.
- W3125304810 cites W2161650275 @default.
- W3125304810 cites W2161817637 @default.
- W3125304810 cites W2327437619 @default.
- W3125304810 cites W2726054049 @default.
- W3125304810 cites W4384455562 @default.
- W3125304810 doi "https://doi.org/10.1186/s12890-020-01390-6" @default.
- W3125304810 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7841898" @default.
- W3125304810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33509141" @default.
- W3125304810 hasPublicationYear "2021" @default.
- W3125304810 type Work @default.
- W3125304810 sameAs 3125304810 @default.
- W3125304810 citedByCount "3" @default.
- W3125304810 countsByYear W31253048102022 @default.
- W3125304810 countsByYear W31253048102023 @default.
- W3125304810 crossrefType "journal-article" @default.
- W3125304810 hasAuthorship W3125304810A5030610788 @default.
- W3125304810 hasAuthorship W3125304810A5037608961 @default.
- W3125304810 hasAuthorship W3125304810A5040886031 @default.
- W3125304810 hasAuthorship W3125304810A5051401384 @default.
- W3125304810 hasAuthorship W3125304810A5083441342 @default.
- W3125304810 hasBestOaLocation W31253048101 @default.
- W3125304810 hasConcept C126322002 @default.
- W3125304810 hasConcept C143998085 @default.
- W3125304810 hasConcept C197934379 @default.
- W3125304810 hasConcept C2776029263 @default.
- W3125304810 hasConcept C2776232967 @default.
- W3125304810 hasConcept C2776256026 @default.
- W3125304810 hasConcept C2778715236 @default.
- W3125304810 hasConcept C2779220645 @default.
- W3125304810 hasConcept C2779422266 @default.
- W3125304810 hasConcept C2992208098 @default.
- W3125304810 hasConcept C71924100 @default.
- W3125304810 hasConcept C90924648 @default.
- W3125304810 hasConceptScore W3125304810C126322002 @default.
- W3125304810 hasConceptScore W3125304810C143998085 @default.
- W3125304810 hasConceptScore W3125304810C197934379 @default.
- W3125304810 hasConceptScore W3125304810C2776029263 @default.
- W3125304810 hasConceptScore W3125304810C2776232967 @default.
- W3125304810 hasConceptScore W3125304810C2776256026 @default.
- W3125304810 hasConceptScore W3125304810C2778715236 @default.
- W3125304810 hasConceptScore W3125304810C2779220645 @default.
- W3125304810 hasConceptScore W3125304810C2779422266 @default.
- W3125304810 hasConceptScore W3125304810C2992208098 @default.
- W3125304810 hasConceptScore W3125304810C71924100 @default.
- W3125304810 hasConceptScore W3125304810C90924648 @default.
- W3125304810 hasIssue "1" @default.
- W3125304810 hasLocation W31253048101 @default.
- W3125304810 hasLocation W31253048102 @default.
- W3125304810 hasOpenAccess W3125304810 @default.
- W3125304810 hasPrimaryLocation W31253048101 @default.
- W3125304810 hasRelatedWork W2109222770 @default.
- W3125304810 hasRelatedWork W2400744927 @default.
- W3125304810 hasRelatedWork W2624310346 @default.
- W3125304810 hasRelatedWork W2941535758 @default.
- W3125304810 hasRelatedWork W3023559395 @default.
- W3125304810 hasRelatedWork W3035529108 @default.
- W3125304810 hasRelatedWork W3047576044 @default.
- W3125304810 hasRelatedWork W3199005851 @default.
- W3125304810 hasRelatedWork W4232445662 @default.
- W3125304810 hasRelatedWork W4383302437 @default.
- W3125304810 hasVolume "21" @default.
- W3125304810 isParatext "false" @default.
- W3125304810 isRetracted "false" @default.
- W3125304810 magId "3125304810" @default.
- W3125304810 workType "article" @default.